Cerity Partners’s UroGen Pharma URGN Stock Holding History

Cerity Partners’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-36,965	Closed	-$554K	–	2412
2024 Q1	$554K	Sell	36,965 -88,261	-70%	-$1.44M	﹤0.01%	1551
2023 Q4	$1.88M	Buy	+125,226	New	+$1.63M	0.01%	786
2023 Q3	–	Sell	-125,226	Closed	-$1.3M	–	1708
2023 Q2	$1.3M	Hold	125,226	–	–	0.01%	842
2023 Q1	$1.16M	Hold	125,226	–	–	﹤0.01%	913
2022 Q4	$1.11M	Hold	125,226	–	–	0.01%	670
2022 Q3	$1.04M	Hold	125,226	–	–	0.01%	510
2022 Q2	$1.03M	Sell	125,226 -3,029	-2%	-$20.8K	0.01%	546
2022 Q1	$1.12M	Hold	128,255	–	–	0.02%	426
2021 Q4	$1.22M	Buy	128,255 +118,214	+1,177%	+$1.67M	0.02%	404
2021 Q3	$169K	Hold	10,041	–	–	﹤0.01%	658
2021 Q2	$153K	Hold	10,041	–	–	﹤0.01%	686
2021 Q1	$196K	Buy	+10,041	New	+$213K	﹤0.01%	667

Other funds holding URGN

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Cerity Partners's URGN Position: Q2 2024 in Review

Cerity Partners sold out of UroGen Pharma (URGN) in Q2 2024, closing a stake of 36,965 shares — an estimated $554K sold.

Cerity Partners first reported a position in URGN in Q1 2021 and held it in 12 quarters. The position peaked at $1.88M in Q4 2023. 115 funds tracked by Wall St. Rank hold URGN as of Q2 2024.

Cerity Partners reported no remaining UroGen Pharma position as of Q2 2024 after selling out during the quarter.
Cerity Partners sold 36,965 UroGen Pharma shares in Q2 2024, an estimated $554K.
Cerity Partners first reported a position in UroGen Pharma in Q1 2021 and held it in 12 quarters.
Cerity Partners's UroGen Pharma position peaked at $1.88M in Q4 2023.
115 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2024.

Based on Cerity Partners's 13F filing for Q2 2024, filed 13 Aug 2024.